Key Highlights

  • Lunai Bioworks (NASDAQ:LNAI) fell 14.12% to USD 0.2530 in early trading on Monday, October 26, 2026, after a Friday close near USD 0.29, following its announcement of a Nasdaq delisting determination on Thursday, October 22, 2026.
  • The exchange is expected to suspend trading at the open on Friday, October 30, 2026, and the company does not intend to arrange over-the-counter quotation for its shares afterwards.
  • Stockholders' deficit was USD 9,024,946 at June 30, 2026, against a required minimum of USD 2,500,000 in stockholders' equity under Nasdaq Listing Rule 5550(b)(1).
  • The board approved voluntary delisting and deregistration, with Form 25 planned on or about Monday, November 2, 2026 and delisting expected around Thursday, November 12, 2026.

Lunai Bioworks (NASDAQ:LNAI) extends its slide on the delisting plan

Lunai Bioworks (NASDAQ:LNAI), an artificial intelligence drug discovery and biodefence company, traded at USD 0.2530 in early trading on Monday, October 26, 2026, down 14.12% after a Friday close of about USD 0.29. The driver is the company's release of Thursday, October 22, 2026, which disclosed that Nasdaq staff had determined to delist the shares after a letter received on Wednesday, October 21, 2026. The company no longer meets the minimum stockholders' equity requirement, and because it is under a mandatory panel monitor, the staff acted directly. The company will not request a hearing. Prices on Monday are intraday, and the market value is near USD 1.3 million, based on the Friday close.

How the Delisting and Deregistration Sequence Works

A delisting determination removes a company from the exchange unless it appeals, and Lunai Bioworks (NASDAQ:LNAI) has chosen not to appeal. The board approved voluntary withdrawal on Thursday, October 22, 2026, citing the staff determination and its financial condition. Trading is expected to be suspended at the open on Friday, October 30, 2026. The company plans to file Form 25, the notice that removes a listing, on or about Monday, November 2, 2026, with delisting expected around Thursday, November 12, 2026. It then intends to file Form 15 to suspend its reporting duties to the SEC, to the extent it is eligible. The company has stated that it does not intend to arrange over-the-counter quotation, which would leave holders with no public market.

Risks and What to Watch

The main risk for Lunai Bioworks (NASDAQ:LNAI) holders is a loss of liquidity: after the suspension on Friday, October 30, 2026, there may be no quoted market, and the end of SEC reporting would reduce the information available. The financial position is weak. Its annual report for the year to June 30, 2026 showed a stockholders' deficit of USD 9,024,946, and a published summary of that filing cites a net loss of USD 3.56 million and a going-concern warning. A sale of shares ahead of the suspension could add selling pressure. Investors should watch trading on Tuesday, October 27, 2026, the final session on Thursday, October 29, 2026, the Form 25 filing on or about Monday, November 2, 2026 and the Fed decision on Wednesday, October 28, 2026.

Where Things Stand

The answer is that the 14.12% fall to USD 0.2530 reflects the countdown to a Nasdaq suspension and a stated plan to leave the public markets. Lunai Bioworks (NASDAQ:LNAI) has a stockholders' deficit of USD 9,024,946 and has said it will not seek over-the-counter quotation. The next catalysts are the suspension at the open on Friday, October 30, 2026, Form 25 on or about Monday, November 2, 2026 and delisting around Thursday, November 12, 2026. Delisted shares can become difficult to sell, and this is not investment advice.